Improving quality of life and outcomes for chemotherapy patients and others at risk of severe neutropenia, through the first noninvasive white cell monitor.
This is an investigational device. It is not for sale. The claims made on this website have not been evaluated by the FDA or the CE Mark authorities.
Carlos Castro Gonzalez, PhD
Chief Executive Officer
Developed prior licensed technologies for medical devices. Track record raising non-dilutive funds
Ian Butterworth, MSc
Chief Technical Officer
Measurement systems expert. Developed hardware and software for four prior medical device start-ups
Aurelien Bourquard, PhD
Chief Data Scientist
Designed cutting-edge AI and computer vision methods for biomedical imaging
Alvaro Sanchez-Ferro, MD
Chief Medical Officer
Led numerous human studies for clinical validation of new technologies
Business Development and Engineering
Alberto Pablo Trinidad
Developer of deep learning and computer vision algorithms
Dana Al-Ansari, MBA
Developed customer insights and use-case validation for neutropenia detecting technologies
Board of Directors
Awards and Support
Our Origin Story
Leuko is a company that spun out from the Massachusetts Institute of Technology and the Madrid–MIT M+Visión Consortium. The founders were research fellows in a biomedical technology innovation initiative who felt compelled to solve a big unmet medical need for cancer patients undergoing chemotherapy.
You can read more about our story at the MIT Innovation Initiative